Long-term Elexacaftor/Tezacaftor/Ivacaftor Therapy Improves Glucose Tolerance and Lowers Insulin Concentrations in Cystic Fibrosis
Authors' conclusion
ETI therapy is associated with improved glucose tolerance and lower insulin concentrations on OGTT, suggesting metabolic benefits of CFTR modulation.
Study context
- Population
- People with cystic fibrosis (CF) (median age 23 years); OGTT data within a 10-year window (5 years pre- to 5 years post-ETI)101 individuals
- Participants
- 199 vs 378
- Exposure
- During elexacaftor/tezacaftor/ivacaftor (ETI) vs pre-ETI
- During ETIn = 199
- Pre-ETIn = 378reference
- Outcome
- Mean OGTT glucose and insulin concentrations
Methodological detailspre-post comparison
- Pre-post comparison
Main finding
As reported in the abstract
- Significant glucose changes after 60 and 90 min and insulin after 30, 60, 90 and 120 min
- During ETI vs Pre-ETI: P = 0.015
- During ETI vs Pre-ETI: P < 0.001
Observational data: associations, not effects.
Further findings
Glucose metabolism category during ETI, by age (P = .004 for distribution): INDET
P = 0.004
Glucose metabolism category during ETI, by age: IGT
- Glucose metabolism category during ETI, by age (P = .004 for distribution): INDET: distribution of glucose metabolism categories differed by age
Insulin sensitivity (Matsuda index) · during ETI
- Insulin sensitivity improved, significant change in Matsuda index
- −0.65, P = .017
Original publication
Long-term Elexacaftor/Tezacaftor/Ivacaftor Therapy Improves Glucose Tolerance and Lowers Insulin Concentrations in Cystic Fibrosis. Endocr Pract. Published 7 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →